Medigene Reports Financial Results and Corporate Update for Q3 2023
October 26, 2023 02:30 ET
|
Medigene AG
Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
October 23, 2023 03:00 ET
|
Medigene AG
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
October 16, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
September 27, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
September 18, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the Baader Investment Conference 2023
September 11, 2023 12:30 ET
|
Medigene AG
Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 11:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...
Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
August 30, 2023 17:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof....
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types
August 23, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, August 23, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to present at the 8th CAR-TCR Summit in Boston
August 22, 2023 10:00 ET
|
Medigene AG
Planegg/Martinsried, August 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for...